Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8500a phase 2 crossover study in Japanese patients with type 2 diabetes mellitus
jRCT2080223072Phase 2
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of firuglipel in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Pancreatic beta cell function.
02
Drugs
firuglipel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223072.